Company Next Pharma Consulting Srl with Fiscal Code 25883632
recorded a turnover of 2024 of
638.655,
with a net profit of
507.139
and having an average number of employees of
2.
The company operates in the field of Alte activităţi de servicii suport pentru întreprinderi n.c.a. having the NACE code 8299.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Next Pharma Consulting Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
29.714
114.876
185.798
192.190
142.758
80.160
205.685
86.464
130.970
638.655
Total Income - EUR
29.714
114.876
185.798
192.190
144.529
80.161
205.685
86.464
130.970
638.683
Total Expenses - EUR
25.679
34.178
79.184
103.701
54.420
56.087
54.874
47.467
51.126
37.238
Gross Profit/Loss - EUR
4.034
80.699
106.614
88.489
90.109
24.074
150.812
38.997
79.844
601.445
Net Profit/Loss - EUR
2.797
67.184
87.128
86.567
88.659
23.352
148.833
38.133
66.788
507.139
Employees
0
0
1
2
2
2
2
2
2
2
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 390.4%, from 130.970 euro in the year 2023, to 638.655 euro in 2024.
The Net Profit increased by 440.724 euro, from 66.788 euro in 2023, to 507.139 in the last year.
Check the financial reports for the company - Next Pharma Consulting Srl
Financial Rating - NEXT PHARMA CONSULTING SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Next Pharma Consulting Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Next Pharma Consulting Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Next Pharma Consulting Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Next Pharma Consulting Srl - CUI 25883632
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Fixed Assets
12.993
32.896
76.775
92.680
121.065
106.251
90.931
83.683
77.594
77.902
Current Assets
129.139
172.772
218.021
223.210
190.727
109.891
112.982
29.977
46.050
410.964
Inventories
879
1.099
2.452
16.604
10.317
10.124
9.930
10.844
10.814
10.776
Receivables
38.794
41.663
45.068
52.743
98.523
96.046
95.444
16.685
16.775
236.820
Cash
89.465
130.010
170.501
153.863
81.888
3.721
7.608
2.448
18.460
163.367
Shareholders Funds
142.225
190.567
274.471
301.554
290.121
195.073
183.571
130.066
122.865
507.201
Social Capital
45
45
44
43
42
41
40
41
40
40
Debts
8.108
36.548
39.252
34.606
42.400
41.405
40.887
4.881
22.557
3.371
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9743
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
Main CAEN
"8299 - 8299"
CAEN Financial Year
7022
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
410.964 euro in 2024 which includes Inventories of
10.776 euro, Receivables of
236.820 euro and cash availability of
163.367 euro.
The company's Equity was valued at
507.201 euro, while total Liabilities amounted to
3.371 euro.
Equity increased by 385.022 euro, from 122.865 euro in 2023, to 507.201 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Next Pharma Consulting Srl